CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
Long-term Outcomes and Risk Factors for Reoperation After Surgical Treatment for Gastrointestinal Crohn Disease According to Anti-tumor Necrosis Factor-α Antibody Use: 35 Years of Experience at a Single Institute in Korea
Sang Mok Lee, Eon Chul Han, Seung-Bum Ryoo, Heung-Kwon Oh, Eun Kyung Choe, Sang Hui Moon, Joo Sung Kim, Hyun Chae Jung, Kyu Joo Park
Ann Coloproctol. 2015;31(4):144-152.   Published online August 31, 2015
DOI: https://doi.org/10.3393/ac.2015.31.4.144

Excel Download

Long-term Outcomes and Risk Factors for Reoperation After Surgical Treatment for Gastrointestinal Crohn Disease According to Anti-tumor Necrosis Factor-α Antibody Use: 35 Years of Experience at a Single Institute in Korea
Annals of Coloproctology. 2015;31(4):144   Crossref logo
Link1

Treatment Options after Anti-TNF Failure
Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease. 2015;229-233   Crossref logo
Link1 Link2

When and How to Stop Anti-TNF Treatment in Inflammatory Bowel Disease: Predictors of Relapse after Stopping Treatment
Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease. 2015;224-228   Crossref logo
Link1 Link2

Induced myelopathy after long-term anti-tumor necrosis factor alpha treatment
Pediatric Rheumatology. 2011;9(S1):   Crossref logo
Link1 Link2 Link3

Risk of Serious Infection
Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease. 2015;147-151   Crossref logo
Link1 Link2

Neutralisation of Soluble Tumor Necrosis Factor
Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease. 2015;83-89   Crossref logo
Link1 Link2

Risk of Non-Hematologic Malignancy with Anti-TNF Therapy in Inflammatory Bowel Diseases
Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease. 2015;138-142   Crossref logo
Link1 Link2

Risk of Lymphoma
Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease. 2015;143-146   Crossref logo
Link1 Link2

Preliminaries
Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease. ;   Crossref logo
Link1 Link2

Long-term clinical and real-world experience with Crohn’s disease treated with anti-tumor necrosis factor-α antibodies
Intestinal Research. 2022;20(4):464-474   Crossref logo
Link1 Link2 Link3